Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
LPM787000048 in Alzheimer Disease: NCT07230652 Clinical Landscape Report 2026
16 October 2026
NCT07230652 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GPV-381 in Alzheimer Disease: ACTRN12625001260415 Clinical Landscape Report 2026
16 October 2026
ACTRN12625001260415 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
N-2-Butyl cyanoacrylate in Abdominal Neoplasms: NCT07230509 Clinical Landscape Report 2026
16 October 2026
NCT07230509 clinical landscape for Abdominal Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Adebrelimab in Pancreatic Cancer: NCT07230301 Clinical Landscape Report 2026
16 October 2026
NCT07230301 clinical landscape for Pancreatic Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HRS-7085 in Ulcerative colitis, active moderate: NCT07229950 Clinical Landscape Report 2026
16 October 2026
NCT07229950 clinical landscape for Ulcerative colitis, active moderate: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
Levetiracetam in Alzheimer Disease: NCT07234695 Clinical Landscape Report 2026
16 October 2026
NCT07234695 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RTR-242 in Alzheimer Disease: ACTRN12625001274460 Clinical Landscape Report 2026
16 October 2026
ACTRN12625001274460 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SSGJ-706 in Pancreatic Ductal Adenocarcinoma: NCT07233850 Clinical Landscape Report 2026
16 October 2026
NCT07233850 clinical landscape for Pancreatic Ductal Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
SHR-1139 in Ulcerative colitis, active moderate: NCT07232576 Clinical Landscape Report 2026
16 October 2026
NCT07232576 clinical landscape for Ulcerative colitis, active moderate: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
HRS-4642 in KRAS G12D mutation pancreatic cancer: NCT07232875 Clinical Landscape Report 2026
16 October 2026
NCT07232875 clinical landscape for KRAS G12D mutation pancreatic cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Serplulimab in Pancreatic carcinoma non-resectable: NCT07235930 Clinical Landscape Report 2026
16 October 2026
NCT07235930 clinical landscape for Pancreatic carcinoma non-resectable: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
Mirikizumab in Colitis, Ulcerative: NCT07235904 Clinical Landscape Report 2026
16 October 2026
NCT07235904 clinical landscape for Colitis, Ulcerative: endpoints, sponsor, phase, geography, readouts, asset context and development white space.